#ScholarRock has won its first product #approval, 14 years after it was founded, as the #FDA gives a green light to its #spinalmuscularatrophy (SMA) therapy Isembyld.
pharmaphorum.com/news/scholar...
pharmaphorum.com/news/scholar...
Scholar Rock gets first drug approval as FDA okays Isembyld
Scholar Rock has won its first product approval, on its second attempt, as the FDA gives a green light to its spinal muscular atrophy drug Isembyld.
pharmaphorum.com
September 14, 2026 at 11:45 AM
#ScholarRock has won its first product #approval, 14 years after it was founded, as the #FDA gives a green light to its #spinalmuscularatrophy (SMA) therapy Isembyld.
pharmaphorum.com/news/scholar...
pharmaphorum.com/news/scholar...
💊 #ScholarRock awaits an FDA decision Sept. 22 on apitegromab, its potential first SMA treatment. If approved, the myostatin blocker could launch this year in the U.S. and top $1B in annual sales later. Details: en.oninvest.com/article/sma-...
SMA drugmaker Scholar Rock may jump on upcoming FDA decision, Freedom Broker thinks – Oninvest
Freedom Broker has issued a short-term trade idea to buy shares of biotech company Scholar Rock ahead of a U.S. regulator’s ruling on the registration of its drug for spinal muscular atrophy (SMA). If...
en.oninvest.com
September 2, 2025 at 4:20 PM
💊 #ScholarRock awaits an FDA decision Sept. 22 on apitegromab, its potential first SMA treatment. If approved, the myostatin blocker could launch this year in the U.S. and top $1B in annual sales later. Details: en.oninvest.com/article/sma-...